Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | acyl-CoA desaturase | 0.0407 | 0.7358 | 1 |
Leishmania major | fatty-acid desaturase, putative | 0.0515 | 1 | 1 |
Brugia malayi | acyl-CoA desaturase | 0.0407 | 0.7358 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0108 | 0 | 0.5 |
Onchocerca volvulus | 0.0515 | 1 | 1 | |
Trypanosoma cruzi | fatty acid desaturase, putative | 0.0407 | 0.7358 | 0.7358 |
Toxoplasma gondii | sphingolipid delta 4 desaturase/c-4 hydroxylase protein des2 family protein | 0.0108 | 0 | 0.5 |
Mycobacterium ulcerans | linoleoyl-CoA desaturase, DesA3_2 | 0.0108 | 0 | 0.5 |
Echinococcus multilocularis | Peptidase M, neutral zinc metallopeptidases, zinc binding site | 0.0108 | 0 | 0.5 |
Plasmodium falciparum | stearoyl-CoA desaturase | 0.0407 | 0.7358 | 0.5 |
Mycobacterium tuberculosis | Possible electron transfer protein FdxB | 0.0108 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable transmembrane alkane 1-monooxygenase AlkB (alkane 1-hydroxylase) (lauric acid omega-hydroxylase) (omega-hydroxylase) (f | 0.0108 | 0 | 0.5 |
Echinococcus granulosus | Sphingolipid delta4 desaturase DES1 | 0.0108 | 0 | 0.5 |
Plasmodium vivax | stearoyl-CoA desaturase (acyl-CoA desaturase, faty acid desaturase), putative | 0.0407 | 0.7358 | 0.5 |
Mycobacterium tuberculosis | Probable conserved membrane protein | 0.0108 | 0 | 0.5 |
Trypanosoma cruzi | fatty acid desaturase, putative | 0.0515 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0108 | 0 | 0.5 |
Trypanosoma cruzi | fatty acid desaturase, putative | 0.0407 | 0.7358 | 0.7358 |
Echinococcus multilocularis | Peptidase M, neutral zinc metallopeptidases, zinc binding site | 0.0108 | 0 | 0.5 |
Mycobacterium ulcerans | linoleoyl-CoA desaturase, DesA3 | 0.0108 | 0 | 0.5 |
Echinococcus granulosus | Fatty acid desaturase type 1 | 0.0108 | 0 | 0.5 |
Mycobacterium ulcerans | linoleoyl-CoA desaturase, DesA3 | 0.0108 | 0 | 0.5 |
Onchocerca volvulus | 0.0515 | 1 | 1 | |
Schistosoma mansoni | fatty acid desaturase | 0.0108 | 0 | 0.5 |
Mycobacterium ulcerans | transmembrane alkane 1-monooxygenase AlkB | 0.0108 | 0 | 0.5 |
Mycobacterium ulcerans | electron transfer protein FdxB | 0.0108 | 0 | 0.5 |
Trypanosoma brucei | fatty acid desaturase, putative | 0.0515 | 1 | 1 |
Echinococcus multilocularis | Fatty acid desaturase, type 1 | 0.0108 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.5119 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.